Piflufolastat F 18 Market
The market for Piflufolastat F 18 was estimated at $412 million in 2024; it is anticipated to increase to $626 million by 2030, with projections indicating growth to around $886 million by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Piflufolastat F 18 Market Outlook
Revenue, 2024
$412M
Forecast, 2034
$826M
CAGR, 2025 - 2034
7.2%
The Piflufolastat F 18 industry revenue is expected to be around $441.9 million in 2025 and expected to showcase growth with 7.2% CAGR between 2025 and 2034. The market continues to gain strategic importance due to the increasing global burden of prostate cancer and the growing emphasis on precision diagnostic imaging in oncology care. Rising adoption of advanced positron emission tomography imaging technologies, combined with improved healthcare infrastructure and expanding nuclear medicine capabilities, is strengthening demand for Piflufolastat F 18 across developed and emerging healthcare markets. Pharmaceutical and diagnostic imaging companies are also increasing investments in radiopharmaceutical innovation to improve early disease detection and treatment planning accuracy. In addition, favorable regulatory support for targeted imaging agents and the growing integration of personalized medicine approaches are reinforcing the product’s long-term clinical and commercial relevance within the oncology diagnostics ecosystem.
Piflufolastat F 18 is a prostate-specific membrane antigen (PSMA)-targeted PET imaging agent primarily used for the detection and localization of prostate cancer lesions in patients with suspected metastasis or recurrence. The radiotracer is valued for its high diagnostic sensitivity, improved imaging clarity, and ability to support accurate disease staging compared with conventional imaging techniques. It is increasingly utilized in oncology centers, specialty diagnostic facilities, and nuclear medicine departments to assist clinicians in treatment selection and patient monitoring. Current market trends include rising adoption of PSMA positron emission tomography imaging protocols, expansion of radiopharmaceutical production infrastructure, and growing clinical research focused on advanced cancer imaging applications. Increasing collaboration between pharmaceutical companies, imaging technology providers, and healthcare institutions is further accelerating innovation and commercial adoption in the global molecular imaging industry.
Market Key Insights
The Piflufolastat F 18 market is projected to grow from $412.2 million in 2024 to $826 million in 2034. This represents a CAGR of 7.2%, reflecting rising demand across Prostate Cancer Diagnosis, Recurrence of Prostate Cancer, and Post Treatment Evaluation.
Progenics Pharmaceuticals, Telix Pharmaceuticals, Blue Earth Diagnostics are among the leading players in this market, shaping its competitive landscape.
U.S. and Germany are the top markets within the Piflufolastat F 18 market and are expected to observe the growth CAGR of 4.7% to 6.9% between 2024 and 2030.
Emerging markets including Brazil, South Africa and India are expected to observe highest growth with CAGR ranging between 8.3% to 9.9%.
Transition like Transition from Conventional Diagnostic Imaging to PSMA Targeted Molecular Imaging has greater influence in United States and Germany market's value chain; and is expected to add $19 million of additional value to Piflufolastat F 18 industry revenue by 2030.
The Piflufolastat F 18 market is set to add $414 million between 2024 and 2034, with manufacturer targeting Breast Cancer & Lung Cancer Application projected to gain a larger market share.
With
anticipated advancements in healthcare increased medical imaging, and
Rise in Cancer Cases Urgent Need for Early Detection, Piflufolastat F 18 market to expand 100% between 2024 and 2034.
Opportunities in the Piflufolastat F 18
Japan presents a strong growth opportunity for the piflufolastat F 18 market due to its rapidly aging population and increasing incidence of prostate cancer. Healthcare providers are expanding investment in molecular imaging technologies and advanced nuclear medicine capabilities to improve early cancer detection and disease staging. PSMA targeted PET imaging agents are gaining preference because they support highly accurate identification of metastatic lesions among elderly patients requiring personalized treatment planning. Demand is also expected to rise most strongly within hospital based oncology imaging applications, particularly in urban healthcare networks integrating precision oncology programs and advanced radiopharmaceutical diagnostic services for high risk prostate cancer management.
Growth Opportunities in North America and Asia-Pacific
North America dominates the piflufolastat F 18 market due to the strong presence of advanced oncology infrastructure, rising prostate cancer prevalence, and increasing adoption of PSMA PET imaging across the United States and Canada. The region benefits from favorable reimbursement frameworks, growing investments in nuclear medicine facilities, and expanding physician preference for precision oncology diagnostics. Major pharmaceutical and radiopharmaceutical companies are actively strengthening competitive positioning through strategic collaborations, product expansion initiatives, and imaging technology integration. Opportunities are particularly strong in recurrent prostate cancer detection and outpatient molecular imaging services, where demand for accurate disease staging continues to rise. In addition, expanding clinical research activities and increasing awareness regarding personalized cancer care are accelerating commercial adoption. However, competitive intensity remains high as imaging providers and diagnostic companies compete to strengthen radiopharmaceutical distribution networks and secure long term contracts with hospitals and specialty oncology centers.
The Asia-Pacific piflufolastat F 18 market is expanding steadily due to improving healthcare infrastructure, increasing prostate cancer diagnosis rates, and growing investment in advanced molecular imaging technologies. Countries including Japan, China, South Korea, and Australia are actively enhancing nuclear medicine capabilities to support precision oncology initiatives and early cancer detection programs. Japan represents a particularly important market because of its aging population and established adoption of advanced diagnostic imaging procedures. China and India are also emerging as significant growth opportunities as healthcare providers expand access to PET imaging and specialty oncology services. Regional competition is increasing with domestic pharmaceutical manufacturers and imaging companies entering the radiopharmaceutical sector through partnerships and technology licensing agreements. Key growth drivers include rising awareness of PSMA PET imaging benefits, expanding oncology research programs, and increasing government support for modern cancer diagnostic infrastructure development.
Market Dynamics and Supply Chain
01
Driver: Rising Adoption of PSMA PET Imaging and Expansion of Precision Oncology Programs
One of the primary drivers supporting the growth of the piflufolastat F 18 market is also the increasing adoption of prostate specific membrane antigen PET imaging combined with the rapid expansion of precision oncology programs. Healthcare providers are also increasingly utilizing PSMA targeted radiotracers because they offer significantly improved sensitivity and lesion detection accuracy compared with conventional diagnostic imaging techniques. This trend is also particularly strong in advanced oncology centers and nuclear medicine facilities focusing on early metastatic identification and personalized cancer treatment planning. Simultaneously, precision oncology initiatives are also accelerating demand for molecular imaging agents capable of supporting patient specific therapeutic decisions. Pharmaceutical companies and diagnostic imaging providers are also investing heavily in radiopharmaceutical innovation, automated production systems, and advanced PET imaging technologies, further strengthening commercial demand for targeted prostate cancer diagnostic solutions across global healthcare markets.
Growing clinical preference for advanced molecular imaging technologies in recurrent prostate cancer detection is also another major factor driving the piflufolastat F 18 market. Physicians and oncology specialists increasingly favor PSMA PET imaging because it enables earlier identification of recurrent lesions even at low prostate specific antigen levels. This capability improves treatment planning efficiency and supports targeted salvage therapy decisions. Rising integration of artificial intelligence assisted PET scan interpretation and advanced hybrid imaging systems is also further improving diagnostic workflow accuracy and operational efficiency in nuclear medicine departments. In addition, ongoing clinical studies evaluating expanded applications of PSMA based radiopharmaceuticals are also creating new opportunities for broader adoption within specialized oncology imaging markets.
02
Restraint: Limited Availability of Specialized PET Imaging Infrastructure Restricting Broader Clinical Adoption
A major restraint affecting the piflufolastat F 18 market is the limited availability of advanced PET imaging infrastructure and radiopharmaceutical handling capabilities across several healthcare systems. The product requires specialized PET scanners, nuclear medicine facilities, and highly controlled radiotracer distribution networks, which remain concentrated mainly in developed urban healthcare markets. Many hospitals in emerging economies still lack sufficient molecular imaging infrastructure and trained nuclear medicine professionals, limiting patient access and slowing adoption rates. This challenge directly impacts market revenue by restricting diagnostic procedure volumes and reducing penetration into underserved regions. High installation and operational costs associated with PET imaging systems further discourage smaller healthcare providers from adopting advanced PSMA imaging solutions.
03
Opportunity: Rising Partnerships Between Radiopharmaceutical Companies and Specialty Oncology Imaging Centers and Increasing Demand Among High Risk Prostate Cancer Patients Seeking Precision Diagnostics
Strategic collaborations between radiopharmaceutical manufacturers and specialty oncology imaging centers are creating major opportunities for piflufolastat F 18 adoption. Companies are increasingly partnering with diagnostic providers, cyclotron operators, and healthcare institutions to strengthen radiotracer distribution efficiency and expand clinical accessibility. These partnerships support faster commercialization of PSMA PET imaging solutions across developed and emerging healthcare markets. The recurrence detection application segment is expected to witness particularly strong growth due to increasing physician demand for accurate post treatment monitoring technologies. Expanding investments in automated radiopharmaceutical production systems and AI assisted PET scan interpretation are also improving workflow efficiency and diagnostic accuracy within specialized oncology imaging facilities.
Growing awareness regarding precision diagnostics among high risk prostate cancer patients is generating substantial commercial opportunities for the piflufolastat F 18 market. Patients and clinicians increasingly prefer advanced PSMA PET imaging because it enables more accurate disease localization and personalized therapeutic decision making compared with traditional imaging approaches. This trend is especially visible in North America and Western Europe, where healthcare systems are emphasizing value based oncology care and early metastatic detection. The prostate cancer diagnosis application segment is expected to experience the fastest expansion, supported by rising adoption of targeted molecular imaging technologies, improved reimbursement support, and increasing integration of precision oncology treatment pathways.
04
Challenge: High Radiopharmaceutical Production Costs and Complex Regulatory Approval Requirements Limiting Expansion
The piflufolastat F 18 market also faces significant challenges due to high radiopharmaceutical production costs and stringent regulatory compliance requirements. Manufacturing fluorine 18 based imaging agents requires specialized cyclotron facilities, short half life logistics management, and strict quality control systems, increasing overall operational expenses for manufacturers and healthcare providers. In addition, regulatory approvals for radiopharmaceutical products often involve lengthy clinical validation and safety assessment processes, delaying commercialization timelines in multiple regions. These factors create pricing pressures and limit accessibility, particularly in cost sensitive healthcare markets. Smaller diagnostic providers may avoid adopting premium PSMA imaging procedures because of reimbursement uncertainty and high procurement expenses, ultimately affecting overall market demand growth.
Supply Chain Landscape
1
Raw Material Procurement
Advanced BioChemicalsPharmCo Labs
2
API Synthesis
Global PharmaTechSynthoChem LLC
3
Production
Radiant PharmaceuticalsTraceLife Sciences
4
Distribution & Marketing
Progenics PharmaceuticalsLantheus Medical Imaging
1
Raw Material Procurement
Advanced BioChemicalsPharmCo Labs
2
API Synthesis
Global PharmaTechSynthoChem LLC
3
Production
Radiant PharmaceuticalsTraceLife Sciences
4
Distribution & Marketing
Progenics PharmaceuticalsLantheus Medical Imaging
Use Cases of Piflufolastat F 18 in Prostate Cancer Diagnosis & Post Treatment Evaluation
Prostate Cancer Diagnosis : Piflufolastat F 18 is widely utilized in prostate cancer diagnosis through prostate specific membrane antigen PET imaging procedures conducted in hospitals, oncology centers, and nuclear medicine facilities. The radiopharmaceutical is primarily administered to patients with suspected high risk or newly diagnosed prostate cancer to improve lesion detection and staging accuracy. Its high affinity for PSMA expressing cells enables clinicians to identify small metastatic lesions that are often difficult to detect using conventional imaging methods. The application is gaining importance due to increasing adoption of precision oncology and advanced molecular imaging technologies. Growing awareness regarding early disease identification and accurate treatment planning is further strengthening demand for PSMA targeted PET diagnostic solutions globally.
Recurrence of Prostate Cancer : The recurrence of prostate cancer represents a major application area for Piflufolastat F 18, particularly among patients experiencing rising prostate specific antigen levels following surgery or radiation therapy. Specialty imaging centers and oncology hospitals increasingly use PSMA PET scans with Piflufolastat F 18 to detect recurrent cancer lesions at very early stages. The radiotracer provides superior sensitivity in identifying localized and distant recurrence compared with traditional imaging techniques, supporting timely therapeutic intervention. This application is especially valuable for guiding salvage therapies and personalized treatment decisions. Rising prevalence of recurrent prostate cancer cases and growing physician preference for highly targeted diagnostic imaging are significantly contributing to expansion of this application segment across developed healthcare markets.
Post Treatment Evaluation : Post treatment evaluation is becoming an important clinical application for Piflufolastat F 18 in monitoring therapeutic effectiveness after prostate cancer treatment. The radiopharmaceutical is commonly used in PET imaging assessments performed in advanced oncology and nuclear medicine centers to evaluate residual disease, metastatic progression, or response to targeted therapies. Its ability to provide highly detailed molecular imaging supports clinicians in determining whether additional treatment or therapy modification is required. The increasing use of personalized medicine and precision cancer management approaches is accelerating adoption within this segment. Healthcare providers are also utilizing PSMA PET imaging to improve long term patient monitoring and optimize clinical outcomes, particularly among high risk prostate cancer populations undergoing complex treatment regimens.
Impact of Industry Transitions on the Piflufolastat F 18 Market
As a core segment of the Pharmaceutical industry,
the Piflufolastat F 18 market develops in line with broader industry shifts.
Over recent years, transitions such as Transition from Conventional Diagnostic Imaging to PSMA Targeted Molecular Imaging and Transition from Hospital Centered Oncology Care to Integrated Precision Medicine Networks have redefined priorities
across the Pharmaceutical sector,
influencing how the Piflufolastat F 18 market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition from Conventional Diagnostic Imaging to PSMA Targeted Molecular Imaging
The piflufolastat F 18 market is driving a major transition from conventional diagnostic imaging approaches toward PSMA targeted molecular imaging in prostate cancer care. Healthcare providers are increasingly replacing traditional CT and bone scan procedures with advanced PET imaging solutions that offer improved disease localization and personalized treatment planning capabilities. This transition is significantly influencing the nuclear medicine and radiopharmaceutical industries, where investment in PET imaging infrastructure, cyclotron facilities, and molecular imaging technologies is rapidly increasing. Diagnostic imaging companies are also expanding AI integrated imaging platforms and advanced scanner technologies to support rising clinical demand for precision oncology diagnostics and high sensitivity prostate cancer detection services.
02
Transition from Hospital Centered Oncology Care to Integrated Precision Medicine Networks
The industry is also transitioning from traditional hospital centered oncology models toward integrated precision medicine networks supported by advanced imaging diagnostics such as piflufolastat F 18. Oncology centers, specialty imaging facilities, telehealth providers, and pharmaceutical companies are increasingly collaborating to create more personalized cancer management pathways. This shift is expanding the role of outpatient diagnostic imaging and long term disease monitoring services within the broader healthcare ecosystem. The transition is creating growth opportunities for specialty pharmacies, radiopharmaceutical logistics providers, and digital healthcare platforms focused on oncology care coordination. Increasing demand for patient specific treatment strategies is further accelerating integration of molecular imaging into multidisciplinary cancer management programs globally.